tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Astellas Pharma’s ASP3021 Study: A New Hope for AMD Patients?
PremiumCompany AnnouncementsAstellas Pharma’s ASP3021 Study: A New Hope for AMD Patients?
2M ago
Astellas Pharma’s Peficitinib Study: Key Insights for Investors
Premium
Company Announcements
Astellas Pharma’s Peficitinib Study: Key Insights for Investors
2M ago
Astellas Pharma’s Innovative Bladder Device: A Game Changer in Urinary Health?
Premium
Company Announcements
Astellas Pharma’s Innovative Bladder Device: A Game Changer in Urinary Health?
2M ago
Astellas Pharma’s GLEAM Trial Falls Short of Primary Endpoint in Pancreatic Cancer Study
PremiumCompany AnnouncementsAstellas Pharma’s GLEAM Trial Falls Short of Primary Endpoint in Pancreatic Cancer Study
3M ago
Astellas Pharma’s IZERVAY Gains Conditional Approval in Japan for Geographic Atrophy
Premium
Company Announcements
Astellas Pharma’s IZERVAY Gains Conditional Approval in Japan for Geographic Atrophy
3M ago
Astellas Pharma: Hold Rating Amid Growth Challenges and Product Limitations
Premium
Ratings
Astellas Pharma: Hold Rating Amid Growth Challenges and Product Limitations
4M ago
Astellas Pharma’s Phase 3 Study on Fezolinetant: A Potential Game-Changer for Menopausal Hot Flashes
PremiumCompany AnnouncementsAstellas Pharma’s Phase 3 Study on Fezolinetant: A Potential Game-Changer for Menopausal Hot Flashes
5M ago
Astellas Pharma’s ASP3082 Study: A Potential Game-Changer in Cancer Treatment
Premium
Company Announcements
Astellas Pharma’s ASP3082 Study: A Potential Game-Changer in Cancer Treatment
5M ago
Astellas Pharma’s Fezolinetant Study: A Potential Game-Changer for Menopause Treatment
Premium
Company Announcements
Astellas Pharma’s Fezolinetant Study: A Potential Game-Changer for Menopause Treatment
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100